Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARDXNASDAQ:COLLNASDAQ:NRIXNASDAQ:OVAS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDXArdelyx$3.60-3.2%$4.18$3.21▼$8.06$861.32M0.594.53 million shs6.00 million shsCOLLCollegium Pharmaceutical$29.18-1.4%$28.18$23.23▼$42.29$937.61M0.63413,394 shs227,489 shsNRIXNurix Therapeutics$11.93-0.3%$10.62$8.18▼$29.56$909.50M2.15882,457 shs779,250 shsOVASOvaScience$6.61-7.0%$12.74$0.66▼$1.52$236.84M3.11163,131 shs155,687 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDXArdelyx-3.23%-2.17%+9.76%-34.19%-46.19%COLLCollegium Pharmaceutical-1.42%-3.38%+0.38%-0.95%-8.47%NRIXNurix Therapeutics-0.25%-6.65%+24.53%-12.21%-27.70%OVASOvaScience-4.82%-10.45%+4.71%+746.83%+130.10%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARDXArdelyx3.9249 of 5 stars3.51.00.04.42.22.50.6COLLCollegium Pharmaceutical3.9981 of 5 stars3.41.00.03.02.10.82.5NRIXNurix Therapeutics2.2459 of 5 stars4.41.00.00.02.50.80.0OVASOvaScienceN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARDXArdelyx 2.90Moderate Buy$10.39188.58% UpsideCOLLCollegium Pharmaceutical 2.75Moderate Buy$43.7549.93% UpsideNRIXNurix Therapeutics 2.83Moderate Buy$30.18152.95% UpsideOVASOvaScience 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest OVAS, ARDX, COLL, and NRIX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/9/2025COLLCollegium PharmaceuticalPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$36.00 ➝ $37.005/2/2025ARDXArdelyxCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $10.005/2/2025ARDXArdelyxRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Outperform$11.004/29/2025NRIXNurix TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.00 ➝ $27.004/9/2025COLLCollegium PharmaceuticalNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$46.00 ➝ $46.004/9/2025NRIXNurix TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$32.00 ➝ $25.004/9/2025NRIXNurix TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$36.00 ➝ $35.004/9/2025NRIXNurix TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$28.00 ➝ $27.004/2/2025NRIXNurix TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.00 ➝ $36.003/24/2025COLLCollegium PharmaceuticalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.00 ➝ $50.003/17/2025NRIXNurix TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARDXArdelyx$361.71M2.38N/AN/A$0.73 per share4.93COLLCollegium Pharmaceutical$664.28M1.41$10.57 per share2.76$5.99 per share4.87NRIXNurix Therapeutics$56.42M16.12N/AN/A$7.44 per share1.60OVASOvaScience$290K816.68N/AN/A$1.80 per share3.67Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARDXArdelyx-$39.14M-$0.22N/A11.61N/A-11.73%-24.87%-10.51%7/30/2025 (Estimated)COLLCollegium Pharmaceutical$48.15M$1.2212.584.85N/A14.78%104.67%18.38%8/6/2025 (Estimated)NRIXNurix Therapeutics-$193.57M-$2.80N/AN/AN/A-354.85%-53.65%-38.59%7/10/2025 (Estimated)OVASOvaScience-$50.97MN/A0.00∞N/A-10,128.37%-47.06%-42.39%N/ALatest OVAS, ARDX, COLL, and NRIX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/10/2025Q2 2025NRIXNurix Therapeutics-$0.73N/AN/AN/A$16.26 millionN/A5/8/2025Q1 2025COLLCollegium Pharmaceutical$1.50$1.49-$0.01$0.07$174.96 million$177.76 million5/1/2025Q1 2025ARDXArdelyx-$0.10-$0.17-$0.07-$0.17$79.40 million$74.11 million4/8/2025Q1 2025NRIXNurix Therapeutics-$0.72-$0.67+$0.05-$0.67$12.78 million$18.45 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARDXArdelyxN/AN/AN/AN/AN/ACOLLCollegium PharmaceuticalN/AN/AN/AN/AN/ANRIXNurix TherapeuticsN/AN/AN/AN/AN/AOVASOvaScienceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARDXArdelyx0.874.584.31COLLCollegium Pharmaceutical3.430.970.88NRIXNurix TherapeuticsN/A6.466.46OVASOvaScienceN/A12.6212.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARDXArdelyx58.92%COLLCollegium PharmaceuticalN/ANRIXNurix TherapeuticsN/AOVASOvaScience22.52%Insider OwnershipCompanyInsider OwnershipARDXArdelyx4.80%COLLCollegium Pharmaceutical2.51%NRIXNurix Therapeutics7.40%OVASOvaScience7.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARDXArdelyx90239.26 million222.88 millionOptionableCOLLCollegium Pharmaceutical21032.13 million30.97 millionOptionableNRIXNurix Therapeutics30076.24 million70.42 millionOptionableOVASOvaScienceN/A35.83 millionN/ANot OptionableOVAS, ARDX, COLL, and NRIX HeadlinesRecent News About These CompaniesAssisted Reproductive Technology Market to Surpass USD 40.67 Billion by 2031 | SkyQuest TechnologyAugust 9, 2024 | finance.yahoo.comGlobal Fertility Services Market Report 2024-2032, by Cause of Infertility, Procedure, Service, End-User and RegionMay 21, 2024 | uk.finance.yahoo.comIn Vitro Fertilization Market Will Increase USD 40.6 Billion By 2032 With Around 7.8% CAGRApril 2, 2024 | pharmiweb.comInfertility Services Market Set for Remarkable Expansion, Worth USD 3.8 Billion by 2033 | Market.usMarch 13, 2024 | pharmiweb.comGeneral Catalyst Group V LP's Net WorthFebruary 11, 2024 | benzinga.comGlobal In Vitro Fertilization Market Size To Worth USD 39.12 Billion By 2032 | CAGR of 5.5%December 7, 2023 | finance.yahoo.comOvascience (OVAS) Stock Drops After Pricing Public OfferingNovember 4, 2023 | thestreet.comGlobal Retail Automation Market Size 2023-2027 | Drivers, Product Types, Applications, Growth Analysis and ForecastJune 30, 2023 | finance.yahoo.comTMRW Life Sciences Names Louis Villalba Chief Executive OfficerJune 27, 2023 | markets.businessinsider.comIVF Devices and Consumables Market Research Report 2023 Future Opportunities, Latest Trends, In-depth Analysis, and Forecast To 2030June 22, 2023 | marketwatch.comOcuTerra Appoints Bill Steinkrauss as Chief Financial OfficerJune 1, 2023 | finance.yahoo.comIVF Market Business Approaches by 2030May 15, 2023 | marketwatch.comIVF Devices Market is Predicted to Reach US$ 6367 million by 2027 ... - StreetBuzzMay 14, 2023 | news.google.comSemen Analysis System Market SWOT analysis of key factors to ... - StreetBuzzMay 13, 2023 | news.google.comDonor Egg IVF Treatment Market Statistics, Share Price, Growth ... - Digital JournalMay 12, 2023 | news.google.comIVF Instruments Market Insights, Rising Trends and Global Demand ... - Cottonwood Holladay JournalMay 11, 2023 | news.google.comAssisted Reproductive Technologies (ART) Market Size Growth and ... - Cottonwood Holladay JournalMay 10, 2023 | news.google.comAssisted Reproductive Technology Market Expected to Reach USD 54.75 Billion by 2028 at a 9.7% CAGR - openPRMay 10, 2023 | news.google.comGlobal Assisted Reproductive Technology Market Global Segments ... - Cottonwood Holladay JournalMay 9, 2023 | news.google.comIn Vitro Fertilization Market is Expected to Reach USD 36.51 Billion ... - EIN NewsMay 9, 2023 | news.google.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings3 Penny Stocks Analysts Believe Are Headed HigherBy Chris Markoch | June 4, 2025View 3 Penny Stocks Analysts Believe Are Headed HigherOVAS, ARDX, COLL, and NRIX Company DescriptionsArdelyx NASDAQ:ARDX$3.60 -0.12 (-3.23%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$3.59 -0.01 (-0.28%) As of 06/13/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.Collegium Pharmaceutical NASDAQ:COLL$29.18 -0.42 (-1.42%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$29.18 +0.00 (+0.02%) As of 06/13/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.Nurix Therapeutics NASDAQ:NRIX$11.93 -0.03 (-0.25%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$12.12 +0.19 (+1.58%) As of 06/13/2025 05:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.OvaScience NASDAQ:OVASMillendo Therapeutics, Inc. is a biopharmaceutical company, which engages in seeking distinct and transformative treatments where there is a significant unmet medical need. The company was founded by Julia C. Owens in January 2012 and is headquartered in Ann Arbor, MI. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Fastenal Stock After Split: Poised for 5 More Years of Gains Analysts Love Lovesac, But Investors Should Be Cautious Oracle’s Cloud Boom Is Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
